A jab that could protect against HIV for a year at a time, and other highlights from major conference

Posted in: Access to Medicines, Focus, Healthcare system, HIV/AIDS, InFocus, Latest, Spotlight

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.

A jab that could protect against HIV for a year at a time, and other highlights from major conference

In-depth: How do long-acting HIV treatments work?

Posted in: HIV/AIDS, Latest, Science

Researchers have been trying to develop antiretroviral medicines that can last for weeks, months or even years per dose. Two such long-acting formulations have been approved in South Africa, but several more are on the horizon. Elri Voigt explores the science behind what makes a formulation long-acting and takes a look at some particularly exciting prospects.